Esperion Therapeutics Reports 12% Revenue Growth to $82.4 Million in Q2 2025

Esperion Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $82.4 million, a 12% increase from $73.8 million in the same period last year. This growth was primarily driven by a significant rise in product sales, which reached $40.3 million, up from $28.3 million in the prior year. However, collaboration revenue saw a decline, totaling $42.1 million compared to $45.5 million in the previous year, largely due to the absence of milestone payments that were recognized in the prior period.

The company's operating expenses for the second quarter were $75.3 million, an increase from $71.3 million in the same quarter of 2024. The cost of goods sold surged to $28.5 million, reflecting higher product sales, while research and development expenses decreased to $7.2 million from $11.5 million, indicating a reduction in clinical study costs. Selling, general, and administrative expenses also fell to $39.5 million from $44.2 million, attributed to lower marketing expenditures. Despite these efforts, Esperion reported a net loss of $12.7 million for the quarter, a significant improvement from the $61.9 million loss recorded in the same quarter of the previous year.

In terms of strategic developments, Esperion has made notable progress in expanding its product offerings and market presence. The company received expanded indications for its lead products, NEXLETOL and NEXLIZET, from the FDA in March 2024, which are now indicated for cardiovascular risk reduction. Additionally, the company is pursuing international approvals, with applications filed in Canada and Japan, and expects further approvals in various territories through its collaboration partners.

Operationally, Esperion's inventory levels increased to $114.5 million as of June 30, 2025, compared to $94.5 million at the end of 2024, reflecting the company's efforts to meet growing demand for its products. The company also reported a cash balance of $86.1 million, down from $144.8 million at the end of 2024, indicating a need for continued financial management as it navigates ongoing operational costs and investments in product commercialization.

Looking ahead, Esperion anticipates continued operating losses as it invests in the commercialization of its products and the development of its pipeline. The company is exploring various financing options, including collaborations and equity offerings, to support its operations. Management remains optimistic about the potential for revenue growth from product sales and collaboration agreements, although it acknowledges the inherent risks and uncertainties in achieving profitability in the near term.